Stock Track | Bionano Genomics Plunges on Weak Q3 Revenue Outlook

Stock Track

2024-10-10

Shares of Bionano Genomics (NASDAQ: BNGO) plummeted by 5.42% on Tuesday after the company lowered its revenue guidance for the third quarter of 2024.

The genomic analysis company now expects revenue for Q3 2024 to range between $6.5 million and $6.8 million, down significantly from its previous guidance of $7.9 million to $8.9 million. The revised outlook also fell short of the consensus estimate of $7.85 million.

In a press release, Bionano CEO Erik Holmlin cited a strategic shift toward driving utilization of its optical genome mapping (OGM) technology among existing customers rather than emphasizing new system placements. He also acknowledged headwinds experienced in the capital equipment sector, which likely impacted the company's ability to sell new OGM systems during the quarter.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1144253749"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144253749\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1144253749?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-10 21:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144253749","market":"us","top_or_hot":-1,"title":"Stock Track | Bionano Genomics Plunges on Weak Q3 Revenue Outlook","media":"Stock Track","content":"<html><body><p>Shares of Bionano Genomics (NASDAQ: BNGO) plummeted by 5.42% on Tuesday after the company lowered its revenue guidance for the third quarter of 2024.</p>\n<p>The genomic analysis company now expects revenue for Q3 2024 to range between $6.5 million and $6.8 million, down significantly from its previous guidance of $7.9 million to $8.9 million. The revised outlook also fell short of the consensus estimate of $7.85 million.</p>\n<p>In a press release, Bionano CEO Erik Holmlin cited a strategic shift toward driving utilization of its optical genome mapping (OGM) technology among existing customers rather than emphasizing new system placements. He also acknowledged headwinds experienced in the capital equipment sector, which likely impacted the company's ability to sell new OGM systems during the quarter.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | Bionano Genomics Plunges on Weak Q3 Revenue Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bionano Genomics Plunges on Weak Q3 Revenue Outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-10-10 21:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Bionano Genomics (NASDAQ: BNGO) plummeted by 5.42% on Tuesday after the company lowered its revenue guidance for the third quarter of 2024.</p>\n<p>The genomic analysis company now expects revenue for Q3 2024 to range between $6.5 million and $6.8 million, down significantly from its previous guidance of $7.9 million to $8.9 million. The revised outlook also fell short of the consensus estimate of $7.85 million.</p>\n<p>In a press release, Bionano CEO Erik Holmlin cited a strategic shift toward driving utilization of its optical genome mapping (OGM) technology among existing customers rather than emphasizing new system placements. He also acknowledged headwinds experienced in the capital equipment sector, which likely impacted the company's ability to sell new OGM systems during the quarter.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"","article_id":"1144253749","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144253749","pubTimestamp":1728568716,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Bionano Genomics  plummeted by 5.42% on Tuesday after the company lowered its revenue guidance for the third quarter of 2024.The genomic analysis company now expects revenue for Q3 2024 to range between $6.5 million and $6.8 million, down significantly from its previous guidance of $7.9 million to $8.9 million. The revised outlook also fell short of the consensus estimate of $7.85 million.In a press release, Bionano CEO Erik Holmlin cited a strategic shift toward driving utilization of","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"股票赛道Bionano Genomics因第三季度收入前景疲软而暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":1},"content_text":"Shares of Bionano Genomics (NASDAQ: BNGO) plummeted by 5.42% on Tuesday after the company lowered its revenue guidance for the third quarter of 2024.\nThe genomic analysis company now expects revenue for Q3 2024 to range between $6.5 million and $6.8 million, down significantly from its previous guidance of $7.9 million to $8.9 million. The revised outlook also fell short of the consensus estimate of $7.85 million.\nIn a press release, Bionano CEO Erik Holmlin cited a strategic shift toward driving utilization of its optical genome mapping (OGM) technology among existing customers rather than emphasizing new system placements. He also acknowledged headwinds experienced in the capital equipment sector, which likely impacted the company's ability to sell new OGM systems during the quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}